Kim Jae Young, Lim Hyunsun, Park Cheol Ho, Kim Hyung Woo, Chang Tae Ik, Han Seung Hyeok
Department of Internal Medicine, National Health Insurance Service Ilsan Hospital, Goyang-si, Republic of Korea.
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
Clin J Am Soc Nephrol. 2025 Mar 1;20(3):387-396. doi: 10.2215/CJN.0000000619. Epub 2024 Nov 14.
The association between aspirin use and risk of the first cardiovascular event was NS in patients with CKD. Compared with nonusers, aspirin users had an increased risk of significant bleeding events. Aspirin prescription for the primary prevention of cardiovascular disease in patients with CKD needs careful consideration.
Despite the high cardiovascular risk in patients with CKD, the role of aspirin in primary prevention remains unclear. This study aimed to investigate the association between aspirin initiation in adults with CKD without prior cardiovascular disease (CVD) and the first cardiovascular and bleeding events using Korean nationwide cohort data.
Among individuals aged 40–79 years with an eGFR between 15 and 59 ml/min per 1.73 m who underwent routine health examinations between 2011 and 2016, 15,861 individuals who were newly prescribed aspirin at a dose of 100 mg/d were matched with 79,305 aspirin non-users by propensity score matching. The primary efficacy outcome was a composite of nonfatal atherosclerotic CVD or cardiovascular death. The primary safety outcome was hospitalization due to intracranial or gastrointestinal bleeding.
During a mean follow-up of 6.9±2.9 years, the incidence rates for the primary efficacy outcome in aspirin users and nonusers were 8.0 and 9.0 per 1000 person-years, respectively. Aspirin therapy initiation was not associated with the primary efficacy outcome (hazard ratio, 0.93; 95% confidence intervals, 0.86 to 1.04). However, the primary safety outcome of major bleeding was more frequent in aspirin users than in nonusers (6.7 versus 4.7 per 1000 person-years). The hazard ratio for this outcome in aspirin users versus nonusers was 1.45 (95% confidence intervals, 1.32 to 1.59).
No association was observed between aspirin use and the risk of nonfatal atherosclerotic CVD or cardiovascular death in patients with CKD stages G3 and G4 without prior CVD. Aspirin use was associated with higher risk of major bleeding.
在慢性肾脏病(CKD)患者中,阿司匹林使用与首次心血管事件风险之间无统计学意义。与未使用者相比,阿司匹林使用者发生严重出血事件的风险增加。CKD患者心血管疾病一级预防的阿司匹林处方需要谨慎考虑。
尽管CKD患者心血管风险较高,但阿司匹林在一级预防中的作用仍不明确。本研究旨在利用韩国全国队列数据,调查无既往心血管疾病(CVD)的成年CKD患者开始使用阿司匹林与首次心血管和出血事件之间的关联。
在2011年至2016年期间接受常规健康检查、年龄在40 - 79岁、估算肾小球滤过率(eGFR)为每1.73平方米15至59毫升/分钟的个体中,将15861名新开具100毫克/天剂量阿司匹林的个体与79305名未使用阿司匹林的个体进行倾向得分匹配。主要疗效结局为非致死性动脉粥样硬化性CVD或心血管死亡的复合结局。主要安全结局为因颅内或胃肠道出血住院。
在平均6.9±2.9年的随访期间,阿司匹林使用者和未使用者主要疗效结局的发生率分别为每1000人年8.0例和9.0例。开始使用阿司匹林治疗与主要疗效结局无关(风险比,0.93;95%置信区间,0.86至1.04)。然而,阿司匹林使用者发生大出血的主要安全结局比未使用者更频繁(每1000人年6.7例对4.7例)。阿司匹林使用者与未使用者该结局的风险比为1.45(95%置信区间,1.32至1.59)。
在无既往CVD的G3和G4期CKD患者中,未观察到阿司匹林使用与非致死性动脉粥样硬化性CVD或心血管死亡风险之间的关联。使用阿司匹林与大出血风险较高相关。